Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Abou-Alfa
    Abou-Alfa
  4. Janjigian
    Janjigian
  5. O'Reilly
    O'Reilly
  6. Mauro
    Mauro
  7. Levine
    Levine
  8. Rosenberg
    Rosenberg
  9. Salles
    Salles
  10. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (152)
  2. Solid Tumor Oncology Division (108)
  3. Hematologic Malignancies, Division of (47)
  4. Center for Hematologic Malignancies (43)
  5. Thoracic Oncology (40)
  6. Gastrointestinal Oncology Service (31)
  7. Genitourinary Oncology Service (27)
  8. Lymphoma (17)
  9. GSK Faculty (16)
  10. Adult Leukemia (15)
Search Within
Formats
  1. Meeting Abstract (172)
  2. Journal Article (1)
Groups
  1. Department of Medicine (152)
  2. Solid Tumor Oncology Division (108)
  3. Hematologic Malignancies, Division of (47)
  4. Center for Hematologic Malignancies (43)
  5. Thoracic Oncology (40)
  6. Gastrointestinal Oncology Service (31)

More Groups

People
  1. Alexander Drilon (20)
  2. Robert Motzer (20)
  3. Ghassan Abou-Alfa (13)
  4. Matthew Hellmann (8)
  5. Yelena Janjigian (8)
  6. Eileen O'Reilly (7)

More People

Years
  1. 2022 (39)
  2. 2021 (24)
  3. 2020 (36)
  4. 2019 (16)
  5. 2018 (22)
  6. 2017 (10)

More Years

Publishers
  1. S. Karger AG (173)

Results (173)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ZENYTH-ESO Substudy 1 (GSK3901961), cohort 1: A first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer
    Meeting Abstract

    Wermke, M.; Ullrich, R.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib; A next generation; Highly selective; Non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Weirda, W. G.; Cheah, C. Y.; Roeker, L. E.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14
    Meeting Abstract

    Salwender, H.; Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R.; Byrne, J.; Eliason, L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Interim analysis of VISION cohorts A and C
    Meeting Abstract

    Griesinger, F.; Thomas, M.; Reinmuth, N.; Wermke, M.; Overbeck, T.; Alt, J.; Henschke, S.; Wehler, T.; Ochsenreither, S.; Garassino, M. C.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Durability of efficacy with selpercatinib in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Drillon, A. E.; Subbiah, V.; Gautschi, O.; Tomasini, P.; De Braud, F. G.; Solomon, B.; Tan, D. S. W.; Alonso, G.; Wolf, J.; Park, K.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy(IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase 3 MYSTIC trial
    Meeting Abstract

    Peters, S.; Rizvi, N.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Efficacy of niraparib by timing of surgery and residual disease: A post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
    Meeting Abstract

    O'cearbhaill, R.; Grabowski, J.; Pérez-Fidalgo, J. A.; Monk, B. J.; Tusquets, I.; Mccormick, C.; Pradera, J. F.; Moore, R. G.; Vulsteke, C.; Shahin, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Durvalumab (D) + platinum-etoposide (EP) in 1L extensivestage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Meeting Abstract

    Xie, M.; Chugh, P.; Broadhurst, H.; Lai, Z.; Whitston, D.; Paz-Ares, L.; Gay, C.; Byers, L.; Rudin, C. M.; Stewart, R.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA
    Meeting Abstract

    Griesinger, F.; Tsuboi, M.; Weder, W.; Escriu, C.; Blakely, C.; He, J.; Dacic, S.; Yatabe, Y.; Zeng, L.; Walding, A.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 2296-5270 Karger
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG